News and events

Plant-derived extracellular vesicles (EVs) have emerged as a powerful tool in cancer drug delivery. A recent study published in Nature Materials (2024) sheds light on the advantages of using these natural carriers for targeted therapies, addressing a critical need in oncology for more effective, non-toxic delivery systems.

Breast cancer remains a major challenge in oncology, requiring targeted therapies that enhance tumor specificity while minimizing systemic toxicity. Monoclonal antibodies (mAbs) have shown promise, but their large size (~150 kDa), high cost, and limited tumor penetration present obstacles in treatment.

Extracellular vesicles (EVs) are pivotal in biomarker discovery, drug delivery, and regenerative medicine. However, maintaining their structural integrity and biological function remains a major challenge. A recent study published in Journal of Biological Engineering highlights the critical impact of storage conditions on EV bioavailability, shedding light on the risks of EV degradation and altered cargo profiles due to suboptimal preservation.